Ibio Inc
NASDAQ:IBIO

Watchlist Manager
Ibio Inc Logo
Ibio Inc
NASDAQ:IBIO
Watchlist
Price: 1.98 USD 5.32% Market Closed
Market Cap: 74.8m USD

Operating Margin
Ibio Inc

-4 650.5%
Current
-11 728%
Average
-4.2%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-4 650.5%
=
Operating Profit
-18.6m
/
Revenue
400k

Operating Margin Across Competitors

Country Company Market Cap Operating
Margin
US
Ibio Inc
NASDAQ:IBIO
74.8m USD
-4 651%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-17 527%
US
Abbvie Inc
NYSE:ABBV
406.5B USD
33%
US
Amgen Inc
NASDAQ:AMGN
179.1B USD
34%
US
Gilead Sciences Inc
NASDAQ:GILD
154.9B USD
39%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117.6B USD
39%
US
Epizyme Inc
F:EPE
94.1B EUR
-370%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.7B USD
28%
AU
CSL Ltd
ASX:CSL
83B AUD
26%
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
52.8B USD
8%
NL
argenx SE
XBRU:ARGX
44B EUR
22%
No Stocks Found

Ibio Inc
Glance View

Market Cap
74.8m USD
Industry
Biotechnology

iBio, Inc. is a biotechnology company, which engages in the development and manufacture of biotherapeutics. The company is headquartered in New York City, New York and currently employs 105 full-time employees. The company went IPO on 2008-08-18. The firm is focusing its technologies on the research and development of novel products at its Drug Discovery Center in California. The firm through its FastPharming Manufacturing System and GlycaneeringSM Technologies develop its portfolio of proprietary biologic drug candidates. The firm operates through two segments: Biopharmaceuticals, and Bioprocessing. Its Biopharmaceuticals segment is engaged in large molecule discovery, development, and licensing activities. Its Bioprocessing segment is engaged in contract development and manufacturing services for recombinant proteins. Its pipeline includes IBIO-100, IBIO-101, IBIO-202, and IBIO-400. Its subsidiary, iBio CDMO LLC, provides FastPharming Contract Development and Manufacturing Services along with GlycaneeringSM Development Services.

IBIO Intrinsic Value
0.06 USD
Overvaluation 97%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
-4 650.5%
=
Operating Profit
-18.6m
/
Revenue
400k
What is the Operating Margin of Ibio Inc?

Based on Ibio Inc's most recent financial statements, the company has Operating Margin of -4 650.5%.

Back to Top